211 related articles for article (PubMed ID: 11293562)
1. Using forecasting models to estimate the effects of changes in the composition of claims for selective serotonin reuptake inhibitors on expenditures.
Dewa CS; Hoch JS; Goering P
Clin Ther; 2001 Feb; 23(2):292-306. PubMed ID: 11293562
[TBL] [Abstract][Full Text] [Related]
2. Comparing SSRI treatment costs for depression using retrospective claims data: the role of nonrandom selection and skewed data.
Berndt ER; Russell JM; Miceli R; Colucci SV; Xu Y; Grudzinski AN
Value Health; 2000; 3(3):208-21. PubMed ID: 16464185
[TBL] [Abstract][Full Text] [Related]
3. Long-term costs of treatment for depression: impact of drug selection and guideline adherence.
Crown WH; Treglia M; Meneades L; White A
Value Health; 2001; 4(4):295-307. PubMed ID: 11705297
[TBL] [Abstract][Full Text] [Related]
4. Use of Bayesian net benefit regression model to examine the impact of generic drug entry on the cost effectiveness of selective serotonin reuptake inhibitors in elderly depressed patients.
Shih YC; Bekele NB; Xu Y
Pharmacoeconomics; 2007; 25(10):843-62. PubMed ID: 17887806
[TBL] [Abstract][Full Text] [Related]
5. Drug Expenditure, Price, and Utilization in the U.S. Medicaid: A Trend Analysis for SSRI and SNRI Antidepressants from 1991 to 2018.
Alrasheed M; Hincapie AL; Guo JJ
J Ment Health Policy Econ; 2021 Mar; 24(1):3-11. PubMed ID: 33739932
[TBL] [Abstract][Full Text] [Related]
6. Course and cost of treatment for depression with fluoxetine, paroxetine, and sertraline.
Russell JM; Berndt ER; Miceli R; Colucci S; Grudzinski AN
Am J Manag Care; 1999 May; 5(5):597-606. PubMed ID: 10537866
[TBL] [Abstract][Full Text] [Related]
7. Initial results of the use of prescription order change forms to achieve dose form optimization (consolidation and tablet splitting) of SSRI antidepressants in a state Medicaid program.
Hamer AM; Hartung DM; Haxby DG; Ketchum KL; Pollack DA
J Manag Care Pharm; 2006; 12(6):449-56. PubMed ID: 16925452
[TBL] [Abstract][Full Text] [Related]
8. Duration of therapy and health care costs of fluoxetine, paroxetine, and sertraline in 6 health plans.
Polsky D; Onesirosan P; Bauer MS; Glick HA
J Clin Psychiatry; 2002 Feb; 63(2):156-64. PubMed ID: 11874218
[TBL] [Abstract][Full Text] [Related]
9. Tricyclic antidepressant and selective serotonin reuptake inhibitors antidepressant selection and health care costs in the naturalistic setting: a multivariate analysis.
Hylan TR; Crown WH; Meneades L; Heiligenstein JH; Melfi CA; Croghan TW; Buesching DP
J Affect Disord; 1998 Jan; 47(1-3):71-9. PubMed ID: 9476746
[TBL] [Abstract][Full Text] [Related]
10. Strategies to decrease costs of prescribing selective serotonin reuptake inhibitors at a VA Medical Center.
Dobscha SK; Anderson TA; Hoffman WF; Winterbottom LM; Turner EH; Snodgrass LS; Hauser P
Psychiatr Serv; 2003 Feb; 54(2):195-200. PubMed ID: 12556600
[TBL] [Abstract][Full Text] [Related]
11. Economic consequences of selective serotonin reuptake inhibitor use with drugs also metabolized by the cytochrome P-450 system.
Ozminkowski RJ; Hylan TR; Melfi CA; Meneades LM; Crown WH; Croghan TW; Robinson RL
Clin Ther; 1998; 20(4):780-96. PubMed ID: 9737837
[TBL] [Abstract][Full Text] [Related]
12. Utilization, price, and spending trends for antidepressants in the US Medicaid Program.
Chen Y; Kelton CM; Jing Y; Guo JJ; Li X; Patel NC
Res Social Adm Pharm; 2008 Sep; 4(3):244-57. PubMed ID: 18794035
[TBL] [Abstract][Full Text] [Related]
13. Does the use of SSRIs reduce medical care utilization and expenditures?
Chung S
J Ment Health Policy Econ; 2005 Sep; 8(3):119-29. PubMed ID: 16278500
[TBL] [Abstract][Full Text] [Related]
14. Modeling the pharmacoeconomic cost of three selective serotonin reuptake inhibitors.
Nurnberg HG; Hensley PL; Thompson PM; Paine SS
Psychiatr Serv; 1999 Oct; 50(10):1351-3. PubMed ID: 10506306
[TBL] [Abstract][Full Text] [Related]
15. Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline.
Waldinger MD; Hengeveld MW; Zwinderman AH; Olivier B
J Clin Psychopharmacol; 1998 Aug; 18(4):274-81. PubMed ID: 9690692
[TBL] [Abstract][Full Text] [Related]
16. Mortality Risk Among Patients With COVID-19 Prescribed Selective Serotonin Reuptake Inhibitor Antidepressants.
Oskotsky T; Maric I; Tang A; Oskotsky B; Wong RJ; Aghaeepour N; Sirota M; Stevenson DK
JAMA Netw Open; 2021 Nov; 4(11):e2133090. PubMed ID: 34779847
[TBL] [Abstract][Full Text] [Related]
17. Implications of an SSRI generic step therapy pharmacy benefit design: an economic model in anxiety disorders.
Panzer PE; Regan TS; Chiao E; Sarnes MW
Am J Manag Care; 2005 Oct; 11(12 Suppl):S370-9. PubMed ID: 16236019
[TBL] [Abstract][Full Text] [Related]
18. Hypobaric hypoxia exposure in rats differentially alters antidepressant efficacy of the selective serotonin reuptake inhibitors fluoxetine, paroxetine, escitalopram and sertraline.
Kanekar S; Sheth CS; Ombach HJ; Olson PR; Bogdanova OV; Petersen M; Renshaw CE; Sung YH; D'Anci KE; Renshaw PF
Pharmacol Biochem Behav; 2018 Jul; 170():25-35. PubMed ID: 29738811
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of major selective serotonin-reuptake inhibitors in a managed care population.
Panzarino PJ; Xuan J
Manag Care Interface; 2001 Apr; 14(4):59-65. PubMed ID: 11339023
[TBL] [Abstract][Full Text] [Related]
20. Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization.
Sclar DA; Robison LM; Skaer TL; Galin RS; Legg RF; Nemec NL; Hughes TE; Buesching DP; Morgan M
J Int Med Res; 1995; 23(6):395-412. PubMed ID: 8746607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
